MedTrace Logo

COVID-19 Immunologic Antiviral Therapy With Omalizumab

NCT04720612 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2022-11-16

No results posted yet for this study

Summary

To evaluate if omalizumab is effective in decreasing mortality in severe hospitalized COVID-19 cases.

Conditions

  • Covid19

Interventions

BIOLOGICAL

Omalizumab

Single subcutaneous dose of 375mg of omalizumab and standard of care.

OTHER

Placebo

Single subcutaneous dose of normal saline in a syringe identical to that of the omalizumab arm and standard of care.

Sponsors & Collaborators

  • McGill University Health Centre/Research Institute of the McGill University Health Centre

    lead OTHER

Principal Investigators

  • Elena Netchiporouk, MD, MSc · RI-MUHC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-15
Primary Completion
2022-11-07
Completion
2022-12-16

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04720612 on ClinicalTrials.gov